US 11,944,664 B2
Fibroblast growth factor-21-Fc fusion proteins
Brian R. Boettcher, Winchester, MA (US); Shari Lynn Caplan, Lunenburg, MA (US); Douglas S. Daniels, Arlington, MA (US); Norio Hamamatsu, Belmont, MA (US); Stuart Licht, Cambridge, MA (US); and Stephen Craig Weldon, Leominster, MA (US)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Aug. 24, 2021, as Appl. No. 17/410,307.
Application 14/987,338 is a division of application No. 14/630,206, filed on Feb. 24, 2015, granted, now 9,266,935, issued on Feb. 23, 2016.
Application 14/630,206 is a division of application No. 13/626,194, filed on Sep. 25, 2012, granted, now 9,006,400, issued on Apr. 14, 2015.
Application 17/410,307 is a continuation of application No. 16/117,960, filed on Aug. 30, 2018, granted, now 11,129,874.
Application 16/117,960 is a continuation of application No. 14/987,338, filed on Jan. 4, 2016, granted, now 10,076,554, issued on Sep. 18, 2018.
Claims priority of provisional application 61/539,280, filed on Sep. 26, 2011.
Prior Publication US 2021/0386824 A1, Dec. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/50 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61K 38/00 (2006.01)
CPC A61K 38/1825 (2013.01) [A61K 45/06 (2013.01); C07K 14/50 (2013.01); A61K 38/00 (2013.01); C07K 2319/30 (2013.01)] 9 Claims
 
1. A fusion protein comprising a fibroblast growth factor 21 (FGF21) variant and an Fc region, wherein the FGF21 variant comprises an amino acid sequence with at least 95% identity to the full length hFGF21 sequence SEQ ID NO:1, and comprises at least the following mutations relative to SEQ ID NO:1: Q55C, G148C, K150R, P158S, S195A, P199G, and G202A, and one of R105K and A109T.